Beginning in the late 1800s, Eliza Ruhamah Scidmore, U.S. diplomat and writer, spent 24 years advocating for sakura, or Japanese cherry trees, to be planted in Washington, D.C. After unsuccessfully petitioning every U.S. Army Superintendent of Public Buildings and Grounds for over two decades, she wrote a letter to First Lady Helen Herron Taft about…
In his clinic as a third-year fellow at Johns Hopkins Hospital in Baltimore, Ethan Craig, MD, MHS, says it’s not always easy to hear about patients struggling with step therapy or other barriers to treatment. However, as a member of the ACR’s Government Affairs Committee (GAC), he says his work to understand and improve policy…
Greetings, Advocates! Great news for the rheumatology community came on Feb. 9, when the Bipartisan Budget Act of 2018 was enacted. It contains several critical healthcare fixes pertinent to rheumatology. First, after hundreds of emails, meetings, letters to the editor, an op-ed, and a forceful 109-member coalition (led by the ACR and including many state…
Editor’s note: This blog by Dr. Worthing originally appeared on the ACR’s Advocacy Listserv. Here’s a perspective on the current climate in which your government affairs team works. As you read this list of observations, imagine you’re a lawmaker and try to find where the ACR’s agenda fits into the current landscape: Washington is highly…
Editor’s note: This blog by Dr. Worthing originally appeared on the ACR’s Advocacy Listserv. What a month! House Republicans introduced their bill to repeal and replace Obamacare. The ACR has analyzed the bill and believes the American Health Care Act (AHCA) does not go far enough to help Americans with rheumatic diseases. Brief recap: The…
With a new federal administration and Republican-controlled Congress taking the helm in 2017, the ACR Government Affairs Committee has identified top legislative and regulatory priorities for the year. “The main priority is going to be helping represent the rheumatology community as Medicare is reformed, because the era of MACRA started Jan. 1,” says Angus Worthing,…
As he prepares to take on his newest volunteer role with the ACR, leading the Government Affairs Committee (GAC), Angus Worthing, MD, FACR, FACP, is looking forward to making the most of the opportunities that a unified government can offer the ACR in advocating for rheumatology care. “Advocacy is an investment in our profession—regardless of…
Debate continues about how biosimilars that are emerging to treat rheumatic diseases will be named and monitored, said panelists at a recent meeting in Washington, D.C.—Biosimilars in the United States: Next Steps. Angus Worthing, MD, FACR, FACP, a member of the ACR’s Government Affairs Committee, shared rheumatologists’ concerns as these new therapies come to market….
After its December meeting, the ACR Government Affairs Committee has determined the federal and state issues the College will focus its advocacy efforts on in 2016. These issues include ensuring implementation of the Medicare Access & CHIP Reauthorization Act of 2015 protects rheumatologists, creating an arthritis research program at the Department of Defense and more…